Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 26;21(3):25.
doi: 10.1007/s11912-019-0769-3.

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Laura M Spring  1 , Seth A Wander  1 , Mark Zangardi  1 , Aditya Bardia  2
Affiliations
Review

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Laura M Spring et al. Curr Oncol Rep. .

Abstract

Purpose of review: To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research.

Recent findings: Palbociclib, ribociclib, and abemaciclib are each approved in combination with an aromatase inhibitor or fulvestrant for HR+ MBC. Abemaciclib is also approved as monotherapy for pre-treated patients. Key questions in the field include whether all patients with HR+ MBC should receive a CDK 4/6 inhibitor up front versus later line, impact on overall survival, role of continued CDK 4/6 blockade, mechanism of clinical resistance, and treatment sequencing. The development of CDK 4/6 inhibitors has changed the therapeutic management of HR+ MBC. Additional research is needed to determine optimal treatment sequencing, understand mechanisms governing resistance, and develop novel therapeutic strategies to circumvent or overcome clinical resistance and further improve the outcomes of patients with MBC.

Keywords: Abemaciclib; Clinical trials; Cyclin-dependent kinases 4 and 6; Metastatic breast cancer; Palbociclib; Resistance mechanisms; Ribociclib.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med. 1998;4:1103–6. - PubMed
    1. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–7. - PubMed
    1. Malumbres M Therapeutic opportunities to control tumor cell cycles. Clin Transl Oncol. 2006;8:399–408. - PubMed
    1. Hunt T, Nasmyth K, Novák B. The cell cycle. Philos Trans R Soc Lond B Biol Sci 2011;366:3494–7. - PMC - PubMed
    1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–30. - PubMed

Publication types

MeSH terms